Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Cidara Therapeutics (CDTX) Net Income towards Common Stockholders: 2016-2024

Historic Net Income towards Common Stockholders for Cidara Therapeutics (CDTX) over the last 9 years, with Dec 2024 value amounting to $464,000.

  • Cidara Therapeutics' Net Income towards Common Stockholders fell 18396.22% to -$83.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$132.4 million, marking a year-over-year decrease of 4615.68%. This contributed to the annual value of $464,000 for FY2024, which is 78.41% down from last year.
  • Cidara Therapeutics' Net Income towards Common Stockholders amounted to $464,000 in FY2024, which was down 78.41% from $2.1 million recorded in FY2023.
  • In the past 5 years, Cidara Therapeutics' Net Income towards Common Stockholders ranged from a high of $2.1 million in FY2023 and a low of -$74.9 million during FY2020.
  • For the 3-year period, Cidara Therapeutics' Net Income towards Common Stockholders averaged around -$9.1 million, with its median value being $464,000 (2024).
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first tumbled by 82.21% in 2020, then skyrocketed by 107.21% in 2023.
  • Over the past 5 years, Cidara Therapeutics' Net Income towards Common Stockholders (Yearly) stood at -$74.9 million in 2020, then surged by 43.28% to -$42.5 million in 2021, then grew by 29.83% to -$29.8 million in 2022, then soared by 107.21% to $2.1 million in 2023, then slumped by 78.41% to $464,000 in 2024.